Press Room

Fighting every day to free individuals — and the families who love them — from the harmful effects of muscle-debilitating diseases so they can live longer and grow stronger

Welcome to the MDA Press Room

Raising awareness about how muscular dystrophy, ALS and related muscle-debilitating diseases impact the families we serve is critical for educating people about the urgent need for action and support. 

For Media Inquires 

Mary Fiance
Director of Public Relations and Communications

Nancy Intrator
Director of Communications, Healthcare Partnerships

Media Support

MDA is here to provide assistance with local or national stories about MDA, our lifesaving research and treatments, family stories/interviews, treatment protocols, expert perspectives on diseases in MDA's program, fundraising events, corporate partnerships and other issues related to muscular dystrophy, ALS and related muscle-debilitating diseaes. Call our public relations department at 520-529-5305 or email for assistance.

Guidelines for Reporting & Writing about People with Disabilities 

Recent Press Releases

  • MDA Funds Development of a Critical Biomarker for Charcot Marie Tooth Disease

    $1 million investment aims to accelerate drug development and speed clinical trials to test candidate therapies for CMT

  • Spinal Muscular Atrophy Added to National List of Disorders to Screen Newborns

    Landmark decision for the SMA community recognizes importance of early diagnosis

    CHICAGO, July 5, 2018 – The Muscular Dystrophy Association commends Secretary Azar on adding Spinal Muscular Atrophy (SMA) to the Recommended Uniform Screening Panel (RUSP).

  • MDA Funds Expansion of Facioscapulohumeral Muscular Dystrophy Clinical Research Network

    $1.2 million investment will support seven medical centers that specialize in FSHD research and clinical care

    CHICAGO, June 20, 2018 – The Muscular Dystrophy Association announces the award of an MDA clinical research network grant totaling $1.2 million over three years to develop and maintain a core facioscapulohumeral muscular dystrophy (FSHD) Clinical Trial Research Network (CTRN). The goal of the research network is to spur advances in FSHD research and expedite the development of new therapies for FSHD.

Fastclick tracking Dotomi tracking